OTTIMO PHARMA LIMITED

Active Sandwich

Research and experimental development on biotechnology

4 employees website.com
Life sciences and medical technology Research and experimental development on biotechnology
O

OTTIMO PHARMA LIMITED

Research and experimental development on biotechnology

Founded 3 Mar 2017 Active Sandwich, United Kingdom 4 employees website.com
Life sciences and medical technology Research and experimental development on biotechnology

Previous Company Names

ULTRAHUMAN EIGHT LIMITED 3 Mar 2017 — 23 Sept 2024
Accounts Submitted 16 May 2025 Next due 30 Sept 2026 5 months remaining
Confirmation Submitted 23 Mar 2026 Next due 4 Feb 2027 9 months remaining
Net assets £980K £1M 2023 year on year
Total assets £1M £2M 2023 year on year
Total Liabilities £180K £314K 2023 year on year
Charges None No charges registered

Contact & Details

Contact

Registered Address

C/O Kreston Reeves Llp Innovation House Ramsgate Road Sandwich Kent CT13 9FF United Kingdom

Telephone

0800 000 0000

Email

info@example.com

Website

www.example.com

Full company profile for OTTIMO PHARMA LIMITED (10650475), an active life sciences and medical technology company based in Sandwich, United Kingdom. Incorporated 3 Mar 2017. Research and experimental development on biotechnology. View financials, directors, shareholders, and filings.

Business Summary

This company specializes in providing innovative solutions and services across multiple sectors.

Products & Services

consulting software analytics integration

Reports

Credit Report

In-depth credit score, financial analysis, risk assessment and company intelligence.

Financials

Financials

Period 1 Jan → 31 Dec 2023
Type Total Exemption Full
Next accounts 31 December 2024
Due by 30 September 2025 9 months

Net Assets, Total Assets & Total Liabilities (2017–2023)

Cash in Bank

£984.84k

Decreased by £1.31M (-57%)

Net Assets

£980.05k

Decreased by £1.21M (-55%)

Total Liabilities

£180.39k

Decreased by £313.94k (-64%)

Turnover

N/A

Employees

4

Debt Ratio

16%

Decreased by 2 (-11%)

Financial History

Revenue, profit, EBITDA and key financial figures

2023
Dec Year End
2022
Dec Year End
P&L
Revenue
£142.3M
£128.7M
Gross Profit
£48.2M
£43.1M
Operating Profit
£22.4M
£19.8M
Net Profit
£18.1M
£15.9M
EBITDA
£31.5M
£28.2M
Assets
Cash
£24.7M
£21.3M
Total Assets
£89.4M
£82.1M
Liabilities
Total Liabilities
£45.2M
£41.8M
Key Metrics
Employees
1,247
1,156
Latest Revenue
£142.3M
Latest EBITDA
£31.5M
Cash Position
£24.7M

Funding

Fundraising & Grants

Funding Rounds 3

Investors (9)

Investor NameInvestor SinceParticipating Rounds
Investor 1Dec 2024Series A
Investor 2Dec 2024Series A
Investor 3Dec 2024Series A

Share Capital

Share Capital

Share allotments and capital structure

23 Allotments 10,419,965 Shares £98.58m Total
Date FromShare ClassShares AllottedAmount RaisedPrice/Share
20 Feb 2025199,981£2£0
20 Feb 202566,660£0.667£0
18 Dec 20242,587,089£31.83m£12.304
18 Dec 20241,164,190£12.304£12.304
18 Dec 202468,582£844k£12.304

Officers

Officers

1 active 2 resigned
Status
De Rubertis, FrancescoDirectorItalianSwitzerland5613 Nov 2020Active

Shareholders

Shareholders (30)

Medicxi Secondary I Lp
25.9%
4,386,909
Orbimed Private Investments Ix, Lp
15.3%
2,587,089

Persons with Significant Control

Persons with Significant Control (0)

0 Active 2 Ceased

James Edward Coleman

Ceased 6 Apr 2017

Ceased

William James Jonathan Finlay

Ceased 6 Apr 2017

Ceased

Group Structure

Group Structure

No group structure identified

Charges

Charges

No charges registered

Properties

Properties

0 total

No related properties

Documents

Company Filings

DateCategoryDescriptionDocument
23 Mar 2026Confirmation StatementConfirmation statement made on 2026-01-21 with updates
20 Mar 2026OfficersAppointment of Mr Roger Delemere Dansey as director
26 Feb 2026OfficersChange to director Mr David Epstein on 2026-02-23
26 Feb 2026OfficersChange to director Mr James Sabry on 2026-02-23
26 Feb 2026OfficersChange to director Mr Peter Armstrong Thompson on 2026-02-26
23 Mar 2026 Confirmation Statement

Confirmation statement made on 2026-01-21 with updates

20 Mar 2026 Officers

Appointment of Mr Roger Delemere Dansey as director

26 Feb 2026 Officers

Change to director Mr David Epstein on 2026-02-23

26 Feb 2026 Officers

Change to director Mr James Sabry on 2026-02-23

26 Feb 2026 Officers

Change to director Mr Peter Armstrong Thompson on 2026-02-26

Recent Activity

Latest Activity

Confirmation statement made on 2026-01-21 with updates

4 weeks ago on 23 Mar 2026

Appointment of Mr Roger Delemere Dansey as director

1 months ago on 20 Mar 2026

Change to director Mr David Epstein on 2026-02-23

1 months ago on 26 Feb 2026

Change to director Mr James Sabry on 2026-02-23

1 months ago on 26 Feb 2026

Change to director Mr Peter Armstrong Thompson on 2026-02-26

1 months ago on 26 Feb 2026